Deutsche Bank’s VistaGen Therapeutics VTGN Stock Holding History

Deutsche Bank’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-12,000	Closed	-$2.76K	–	3759
2026 Q2	$2.76K	Buy	+12,000	New	+$7.24K	﹤0.01%	3650
2023 Q3	–	Sell	-4,393	Closed	-$8.22K	–	3827
2023 Q2	$8.22K	Sell	4,393 -4,008	-48%	-$14K	﹤0.01%	3667
2023 Q1	$31.5K	Buy	8,401 +5,484	+188%	+$28.8K	﹤0.01%	3645
2022 Q4	$9.01K	Sell	2,917 -8,057	-73%	-$30.3K	﹤0.01%	3861
2022 Q3	$50K	Buy	10,974 +7,667	+232%	+$76K	﹤0.01%	3590
2022 Q2	$87K	Sell	3,307 -443	-12%	-$15.6K	﹤0.01%	3579
2022 Q1	$140K	Sell	3,750 -417	-10%	-$18.2K	﹤0.01%	3448
2021 Q4	$244K	Buy	4,167 +207	+5%	+$13.5K	﹤0.01%	3281
2021 Q3	$326K	Sell	3,960 -2,261	-36%	-$196K	﹤0.01%	3302
2021 Q2	$588K	Buy	+6,221	New	+$461K	﹤0.01%	3114

Other funds holding VTGN

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Deutsche Bank's VTGN Position: Q3 2026 in Review

Deutsche Bank sold out of VistaGen Therapeutics (VTGN) in Q3 2026, closing a stake of 12,000 shares — an estimated $2.76K sold.

Deutsche Bank first reported a position in VTGN in Q2 2021 and held it in 10 quarters. The position peaked at $588K in Q2 2021. 15 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.

Deutsche Bank reported no remaining VistaGen Therapeutics position as of Q3 2026 after selling out during the quarter.
Deutsche Bank sold 12,000 VistaGen Therapeutics shares in Q3 2026, an estimated $2.76K.
Deutsche Bank first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 10 quarters.
Deutsche Bank's VistaGen Therapeutics position peaked at $588K in Q2 2021.
15 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.